4月23日,强生公司(Johnson & Johnson)的尼卡利单抗(nipocalimab)在中国的上市申请获国家药监局药品审评中心(CDE)受理。其靶向新生儿Fc受体(FcRn)的单克隆抗体疗法被Evaluate列为2025年十大潜在重磅疗法之一,尼卡利单抗的核心机制是通过阻断FcRn介导的IgG抗体再循环,降低血液中的致病性IgG抗体水平,从而缓解自身免疫性疾病的症状。在针对全身性重症...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.